A 48-week, 6-arm, Randomized, Double-blind, Placebo-controlled Multicenter Trial to Assess the Safety and Efficacy of Multiple CFZ533 Doses Administered Subcutaneously in Two Distinct Populations of Patients With Sjogren's Syndrome (TWINSS)
Latest Information Update: 07 Aug 2024
At a glance
- Drugs Iscalimab (Primary)
- Indications Sjogren's syndrome
- Focus Therapeutic Use
- Acronyms TWINSS
- Sponsors Novartis; Novartis Pharmaceuticals
Most Recent Events
- 06 Aug 2024 Primary endpoint has been met. (Change in EULAR Sjgren Syndrome Disease Activity Index (ESSDAI) score from baseline at 24 weeks as compared to placebo)
- 06 Aug 2024 Results published in the Internet Document
- 15 Jun 2024 Results(n=163) evaluating the safety and efficacy of iscalimab in SjD patients, presented at the 25th Annual Congress of the European League Against Rheumatism